Online citations, reference lists, and bibliographies.
← Back to Search

Application Of Polyethyleneglycol (PEG)-modified Liposomes For Oral Vaccine: Effect Of Lipid Dose On Systemic And Mucosal Immunity.

Seiichiro Minato, K. Iwanaga, M. Kakemi, S. Yamashita, N. Oku
Published 2003 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
To examine the systemic and mucosal immunity towards a liposomal antigen in an oral vaccine, we prepared ovalbumin (OVA)-encapsulating polyethyleneglycol (PEG)-modified liposomes and unmodified ones, and orally administered two different concentrations of them to mice. Unmodified liposomes tended to induce a stronger systemic immune response than the PEG-modified ones especially at the higher concentration of liposomes. Whereas at the lower liposome concentration the mucosal immune response was stronger for the PEG-modified liposomes than for the unmodified ones but nearly the same at the higher concentration. The relative amount of immunoglobulin G (IgG) against OVA in the plasma was 1.7-fold higher for a 12.5 micro mol phospholipid dose of PEG-liposomes encapsulating OVA than for a 5.0 micro mol one encapsulating the same amount of OVA. On the contrary, the relative amount of IgA in the intestinal wash was 2.6-fold higher for the 5.0 micro mol phospholipid dose than for the 12.5 micro mol one. These results indicate that OVA encapsulated in a small number of liposomes, especially the PEG-modified ones, is favorable for inducing a mucosal immune response and that the same amount of OVA in a large number of liposomes tends to improve the systemic immune response. A possible explanation for this tendency is the differential release rate of OVA from the liposomes at the intestinal mucosa. Our present study suggests that the dose of liposomes containing antigen is an important factor for controlling the response of systemic and mucosal immune systems.
This paper references
10.1023/A:1018936806278
Stability of Liposomes in Vitro and Their Uptake by Rat Peyer's Patches Following Oral Administration
Y. Aramaki (2004)
Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans.
N. Childers (1990)
10.3109/10611869608996824
Polyethylene glycol modification: relevance of improved methodology to tumour targeting.
G. E. Francis (1996)
10.1023/A:1018945902276
Uptake of Phosphatidylserine Liposomes by Rat Peyer's Patches Following Intraluminal Administration
H. Tomizawa (2004)
10.1016/0014-5793(85)80541-X
The effect of bilayer order and fluidity on detergent‐induced liposome fusion
R. Sáez (1985)
10.1016/0005-2736(96)00090-9
Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation.
R. Zeisig (1996)
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose.
P. Laverman (2000)
10.1016/0005-2736(91)90268-D
Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size.
T. Allen (1991)
10.2174/1381612003398816
Evaluation of drug targeting strategies and liposomal trafficking.
N. Oku (2000)
10.3109/10611869808997864
Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse.
S. Ouadahi (1998)
Targeting to intestinal M cells.
M. Jepson (1996)
10.1128/IAI.69.8.4767-4773.2001
Facilitated Intranasal Induction of Mucosal and Systemic Immunity to Mutans Streptococcal Glucosyltransferase Peptide Vaccines
D. Smith (2001)
10.1016/S0264-410X(01)00119-0
Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice.
M. Lee (2001)
10.1021/JS980235X
Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin.
K. Iwanaga (1999)
10.1016/S0928-0987(01)00175-0
Oral vaccination in man using antigens in particles: current status.
D. Brayden (2001)
10.1016/0168-3659(90)90133-E
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches
J. Eldridge (1990)
10.1016/S0378-5173(97)00237-8
Oral delivery of insulin by using surface coating liposomes improvement of stability of insulin in GI tract
K. Iwanaga (1997)
10.1084/JEM.184.3.1045
Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting
A. Frey (1996)
10.1007/978-3-642-74529-4_5
Liposomes as oral adjuvants.
S. Michalek (1989)
New advances in vaccine delivery systems.
J. Eldridge (1993)
Ph
李幼升 (1989)
10.2165/00003088-199222010-00001
Oral Delivery of Vaccines
D. O'hagan (1992)
10.1007/BF01058904
A new method for assessment of drug disposition in muscle: Application of statistical moment theory to local perfusion systems
T. Kakutani (2005)
10.1128/IAI.58.6.1932-1936.1990
Liposomes containing anti-idiotypic antibodies: an oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces.
S. Jackson (1990)
10.1126/SCIENCE.8493576
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx (1993)
10.1046/j.1440-1711.2000.00898.x
Studies on the IgA‐independent immunological responses in mice to influenza virus challenge after oral vaccination with irradiated whole virus and an erythrocyte complex
B. Lidbury (2000)
Local and systemic immune response to orally administered liposome-associated soluble S. mutans cell wall antigens.
D. Wachsmann (1985)
New perspectives in vaccine development: mucosal immunity to infections.
J. Mcghee (1993)
10.1016/0169-409X(95)00048-C
The importance of gastrointestinal uptake of particles in the design of oral delivery systems
E. Lavelle (1995)



This paper is referenced by
Mise au point de vecteurs colloïdaux pour améliorer l'absorption d'anticancéreux utilisés par voie orale
E. Roger (2009)
10.1016/j.drudis.2012.08.007
Oral delivery of anticancer drugs III: formulation using drug delivery systems.
Silvia Mazzaferro (2013)
Formulation and Evaluation of Megesterol Proniosomal Systems
B. A. Goud (2012)
10.2165/00137696-200301040-00002
Advances in oral vaccine delivery options
D. Webster (2003)
Exploring the therapeutic potential of recombinant AAV vectors in stem cell and transplantation model systems for the treatment of heart diseases
Natascha K. Schuhmann (2008)
10.1002/jps.23773
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.
J. C. Kraft (2014)
10.1007/978-1-4614-0881-9_11
Liposomes in Drug Delivery
V. Torchilin (2012)
10.1002/wnan.131
Topical and mucosal liposomes for vaccine delivery.
E. Romero (2011)
10.1080/10601330903012436
Approaches and issues towards development of efficient mucosal vaccines against pneumonia
Dilip Devineni (2009)
10.1016/j.micpath.2010.04.002
Role of amphotericin B upon enhancement of protective immunity elicited by oral administration with liposome-encapsulated-Japanese encephalitis virus nonstructural protein 1 (NS1) in mice.
T. Lin (2010)
10.1016/j.ijpharm.2012.06.028
Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties.
T. Wang (2012)
10.1016/J.JCONREL.2003.08.001
Solubilization of poorly water soluble drugs in micelles of hydrophobically modified hydroxypropylcellulose copolymers.
M. Francis (2003)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1248/BPB.29.1223
Preparation of double liposomes and their efficiency as an oral vaccine carrier.
Shinsuke Ogue (2006)
10.1089/154732804773099335
Recombinant adeno-associated virus as delivery vector for gene therapy--a review.
Y. Lu (2004)
10.1016/j.jcis.2014.07.035
Investigation of 3-D ordered materials with a high adsorption capacity for BSA and their potential application as an oral vaccine adjuvant.
Q. Zhang (2014)
Development of a targeted nanoscale drug delivery system using pH-responsive DNA-nanoparticle conjugate
L. Song (2013)
10.1007/s13238-015-0164-2
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
S. Wang (2015)
10.1016/S1773-2247(14)50029-9
The potential for production of freeze-dried oral vaccines using alginate hydrogel microspheres as protein carriers
D. Hariyadi (2014)
Symposium- health strategies for the modern pork industry
P. Mitchell (2005)
10.4155/TDE.11.82
Formulation design considerations for oral vaccines.
Jitinder S. Wilkhu (2011)
10.1080/08923973.2017.1392563
Effects of barium chloride adsorbed to polyethylene glycol (PEG) microspheres on co-culture of human blood mononuclear cell and breast cancer cell lines (MCF-7)
Fabiana Helen da Silva (2018)
10.1248/CPB.59.618
Application of Ulex europaeus agglutinin I-modified liposomes for oral vaccine: Ex Vivo bioadhesion and in Vivo immunity.
Kexin Li (2011)
10.1016/J.IJPHARM.2005.04.008
Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system.
Mika Hori (2005)
10.3390/molecules22060870
Preparation, Characterization, and Antioxidant Activity Evaluation of Liposomes Containing Water-Soluble Hydroxytyrosol from Olive
J. Yuan (2017)
10.1016/j.vaccine.2011.05.015
Archaeosomes with encapsulated antigens for oral vaccine delivery.
Z. Li (2011)
10.2147/OTT.S99839
Intracellular calcium is a target of modulation of apoptosis in MCF-7 cells in the presence of IgA adsorbed to polyethylene glycol
A. C. Honório-França (2016)
10.18314/JPT.V1I1.34
Intestinal P-glycoprotein: pharmacokinetic implications and approaches for enhancement of oral bioavailability of its substrates
Manish Nivsarkar (2016)
10.1263/JBB.100.255
O-palmitoylcurdlan sulfate (OPCurS)-coated liposomes for oral drug delivery.
Changmoon Lee (2005)
10.1016/j.jim.2020.112791
Rational application of nanoadjuvant for mucosal vaccine delivery system.
Hitesh Kumar Dewangan (2020)
Towards the development of a multicomponent, nanoscale oral vaccine delivery system targeting infectious bursal disease (IBD)
Wendy Marie Pettit (2013)
10.1517/17425247.2016.1151872
Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery
Shasha Rao (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar